前言：2-4%的非小细胞肺癌患者携带HER-2基因突变。虽然包括泛HER抑制剂、针对性靶向治疗、单克隆抗体、ADC等不同类型的药物在一这领域都有过相关研究，但受限于有限的疗效及药物安全性问题，相关药物未在临床获批应用。目前，HER-2这条通路的药物研 ...

The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a ...

Dr. Valerie Lee discussed emerging targeted therapies and personalized medicine approaches that are showing promise for those with gastrointestinal cancer.

An investigational antibody-drug conjugate proved active and safe for patients with previously treated HER2-mutant non-small ...

My name is Samantha Murrell, and my life changed forever in April 2024 when I was diagnosed with stage 4 non-small cell lung adenocarcinoma (NSCLC) with a HER2 mutation. It all started with what I ...

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.

The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...

Zongertinib is being reviewed for the treatment of adults with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumours have HER2 mutations and who have received prior systemic ...

“Patients with advanced ER+/HER2- metastatic breast cancer face ... of vepdegestrant to give patients whose tumors harbor ESR1 mutations additional time without disease progression, compared ...

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, ...